Inside a Clinical Trial: One Patient's Experience With Islet Transplant and Teplizumab

A participant in an early-stage trial at the University of Chicago received transplanted pancreatic islet cells combined with an immune-protecting drug. We look at what the experience reveals about a potential future treatment approach.

Community video — lay discussion, not peer-reviewed research

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cureresearchclinical trial

Key takeaways

One trial participant has become insulin-free after receiving transplanted pancreatic islet cells alongside the drug teplizumab
This approach differs from past islet transplants by using teplizumab to protect the cells instead of heavy immunosuppressive drugs
This is still an early clinical trial—not yet widely available and not approved as a standard treatment
Real-world experience from trial participants can help the community understand both possibilities and trade-offs of emerging approaches

A Different Kind of Trial Story

For decades, people with Type 1 diabetes have heard the same promise: a cure is just five years away. Understandably, skepticism runs deep. But a clinical trial at the University of Chicago is generating renewed conversation—not because it claims to be a cure, but because it offers a concrete look at what an emerging treatment actually involves.

The trial combines two approaches: transplantation of pancreatic islet cells (the insulin-producing cells that stop working in Type 1) with teplizumab, a drug designed to protect those transplanted cells from the immune system. One trial participant, identified as Patient #9 in the Eladon islet transplant trial, has shared details about living through the procedure and its aftermath.

What Makes This Approach Different

Islet cell transplants are not new, but they have historically faced a major hurdle: keeping the transplanted cells alive requires powerful immunosuppressive medications that carry their own serious side effects and long-term health risks.

This trial explores a different strategy by using teplizumab—a drug that targets specific immune cells involved in attacking the islets—rather than broadly suppressing the entire immune system. The goal is to preserve the transplanted cells' function while reducing the burden of traditional immunosuppression.

Important Context: Early Stage and Limited Access

While one participant's experience of becoming insulin-free is noteworthy, it is critical to understand where this research stands. This is an early clinical trial, meaning it involves a small number of carefully selected participants. Results from one person do not predict outcomes for others, and long-term data on safety and durability are still being collected.

The treatment is not yet approved by regulatory agencies and is not available outside of clinical trials. The decision to participate involves trade-offs—including the surgical procedure itself, ongoing monitoring, and potential risks that researchers are still documenting.

What We Can Learn From This Moment

Hearing directly from someone living through an experimental treatment offers value to the Type 1 community. It shifts the conversation from abstract promises to concrete questions: What does the procedure feel like? What does daily life look like after? What challenges remain?

This trial is one of many research efforts exploring how to restore insulin production or protect islet transplants. Its outcomes—both successes and challenges—will inform the next steps in how the field approaches Type 1 treatment. For now, it represents progress worth following, not a solution ready for widespread use.

Evidence label

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.